<DOC>
	<DOCNO>NCT00001860</DOCNO>
	<brief_summary>The purpose study compare efficacy Sandostatin LAR速 ( Registered Trademark ) Depot transsphenoidal surgery previously untreated acromegalic patient macroadenomas . The primary goal normalize insulin-like growth factor-1 ( IGF-1 ) level . Secondary goal compare Sandostatin LAR速 ( Registered Trademark ) Depot treatment transsphenoidal surgery achieve follow goal : suppress growth hormone level less equal 2.5 ng/mL , relieve clinical sign symptom acromegaly , reduce size macroadenomas , produce side effect , assess prognostic value baseline pituitary adenoma size , extension baseline growth hormone level post-treatment growth hormone IGF-1 level , assess resource utilization treatment type .</brief_summary>
	<brief_title>Sandostatin LAR Depot v . Surgery Treating Acromegaly</brief_title>
	<detailed_description>The purpose study compare efficacy Sandostatin LAR速 ( Registered Trademark ) Depot transsphenoidal surgery previously untreated acromegalic patient macroadenomas . The primary goal normalize insulin-like growth factor-1 ( IGF-1 ) level . Secondary goal compare Sandostatin LAR速 ( Registered Trademark ) Depot treatment transsphenoidal surgery achieve follow goal : suppress growth hormone level less equal 2.5 ng/mL , relieve clinical sign symptom acromegaly , reduce size macroadenomas , produce side effect , assess prognostic value baseline pituitary adenoma size , extension baseline growth hormone level post-treatment growth hormone IGF-1 level , assess resource utilization treatment type .</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Pituitary Neoplasms</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>INCLUSION CRITERIA : Male female patient , 18 year age old . Newly diagnose patient acromegaly , previously untreated . Presence pituitary tumor great 10 mm great diameter ( macroadenoma ) . Lack suppression GH le 2.0 ng/mL use regular GH RIA , less one ng/mL use twosite immunoradiometric chemiluminescent GH assay , oral administration 100 g glucose . IGF1 level upper limit normal ( adjust age gender ) . Demonstrated tolerance test dose s.c. Sandostatin Injection . Demonstrated responsiveness 100 ug s.c. Sandostatin Injection test dose , evidence suppression mean 4HR GH less 5 ng/mL , great 50 % baseline value . Patients able provide write informed consent . EXCLUSION CRITERIA : Patients demonstrate intolerance s.c. Sandostatin ( octreotide acetate ) test dose . Patients receive prior treatment acromegaly , include radiotherapy , octreotide , bromocriptine , lanreotide , prior surgery . Female patient pregnant lactating , childbearing potential practicing medically acceptable method birth control . Patients compression optic chiasm significant enough cause visual field defect automate test . Patients require surgery relief neurologic sign symptom associate tumor . Patients symptomatic cholelithiasis . Patients congestive heart failure ( NYHA Class III IV ) , unstable angina , sustain ventricular tachycardia , ventricular fibrillation , history acute myocardial infarction within three month precede study entry . Patients liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis , persistent ALT , AST , alkaline phosphatase 2X great upper limit normal ; direct bilirubin 10 % great upper limit normal . Patients abnormal clinical laboratory value consider Investigator Sponsor 's Medical Monitor clinically significant could affect interpretation study result . Patients current prior medical condition may interfere conduct study evaluation result opinion Investigator Sponsor 's Medical Monitor . Patients history alcohol drug abuse six month period prior Visit 1 . Patients receive investigational drug within one month prior Visit 1 , plan take investigational drug study . Patients mental impairment limit ability comply study requirement . Patients , reason , unable complete entire study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>Growth Hormone</keyword>
	<keyword>Somatostatin</keyword>
	<keyword>Insulin-like Growth Factor-One</keyword>
	<keyword>Acromegaly</keyword>
	<keyword>Macroadenoma</keyword>
</DOC>